Preparing and use of glu-plasminogen from blood fractions

Abstract

The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.

The claimed invention is: 
     
         1 . A method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation, and a combination of two or more thereof, wherein the patient is administered with a sufficient amount of Glu-plasminogen. 
     
     
         2 . The method of  claim 1 , wherein:
 (a) the ratio of alpha-2-antiplasmin vs. Glu-plasminogen found in the blood of the patient is at least 1.1 fold higher in comparison to the average ratio found throughout population of the same species;   (b) the level of Glu-plasminogen in the blood of the patient is at least 1% (mol/mol) lower in comparison to the average level found throughout population of the same species; or   (c) both (a) and (b).   
     
     
         3 . The method of  claim 1 , wherein the organ failure is or is associated with a pathologic acute renal failure, acute transplant rejection, hypercoagulation, disseminated intravascular coagulation, or thromboembolic event in individual organs. 
     
     
         4 . The method of  claim 1 , wherein the risk of developing organ failure or thromboembolic event is caused by an acquired plasminogen deficiency. 
     
     
         5 . The method of  claim 1 , wherein the risk of organ failure or thromboembolic event is caused by a micro-coagulation disorder. 
     
     
         6 . The method of  claim 1 , wherein the patient is suffering from or is at risk of developing deep vein thrombosis, lung embolism, organ embolisms, or a combination thereof. 
     
     
         7 . The method of  claim 1 , wherein the risk of developing organ failure or a thromboembolic event is caused by an acquired increase of a plasmin inhibitor. 
     
     
         8 . The method of  claim 1 , wherein the disorder is selected from the group consisting of organ failure, deep vein thrombosis, chronic or acute organ embolism, an organ infarction, an acute or chronic inflammation causing a local or generated imbalance of the fibrinolytic system like acute transplant rejection, hypercoagulation, disseminated intravascular coagulation, and a thromboembolic event in an individual organ. 
     
     
         9 . The method of  claim 1 , wherein said Glu-plasminogen forms part of a pharmaceutical composition comprising the Glu-plasminogen and at least one pharmaceutically acceptable carrier. 
     
     
         10 . The method of  claim 1 , wherein the organ failure is or is associated with a pathologic acute renal failure, acute transplant rejection, hypercoagulation, disseminated intravascular coagulation, and thromboembolic event in individual organs, and wherein the organ is selected from the group consisting of heart, lung, and veins. 
     
     
         11 . The method of  claim 1 , wherein the risk of developing organ failure or a thrombotic event is caused by an acquired increase of a plasmin inhibitor, wherein the plasmin inhibitor is alpha-2-antiplasmin. 
     
     
         12 . The method of  claim 1 , wherein the organ failure is associated with hypercoagulation. 
     
     
         13 . The method of  claim 1 , wherein the disorder is selected from the group consisting of organ failure associated with hypercoagulation, a thromboembolic event, arterial obstructive disease, disseminated intravascular coagulation, and a combination of two or more thereof. 
     
     
         14 . The method of  claim 1 , wherein the disorder is associated with hypercoagulation. The method of  claim 1 , wherein the disorder is organ failure. 
     
     
         16 . The method of  claim 1 , wherein the disorder is organ failure associated with hypercoagulation. 
     
     
         17 . The method of  claim 1 , wherein the disorder is organ failure associated with hypercoagulation, wherein the organ is selected from the group consisting of heart, lung, and veins. 
     
     
         18 . The method of  claim 1 , wherein the disorder is a thromboembolic event. 
     
     
         19 . The method of  claim 1 , wherein the disorder is arterial obstructive disease. The method of  claim 1 , wherein the disorder is disseminated intravascular coagulation.